期刊文献+

盐酸坦索罗辛治疗良性前列腺增生症的临床观察 被引量:5

下载PDF
导出
摘要 目的评价单独应用盐酸坦索罗辛治疗良性前列腺增生症的临床疗效。方法选取2008年3月~2011年9月本院泌尿外科门诊符合入选标准的106例连续的前列腺增生症患者,给予盐酸坦索罗辛0.2mg口服,1次/d。治疗8周后复查患者的国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、生活质量评分(QOL)、前列腺体积(V)、残余尿量(RV),并记录各种不良反应。结果 106例患者,1例服药后出现皮肤瘙痒、2例出现体位性低血压、1例腹胀、2例排尿困难症状加重接受手术治疗。100例患者治疗8周后,主观症状、生活质量、最大尿流率和残余尿量与治疗前比较,差异有统计学意义(P<0.05)。前列腺体积较治疗前缩小,但差异无统计学意义(P>0.05)。结论良性前列腺增生症患者单独服用盐酸坦索罗辛也能明显改善主观症状及客观体征,而且具有良好的耐受性。
出处 《中国当代医药》 2012年第7期78-78,81,共2页 China Modern Medicine
  • 相关文献

参考文献6

  • 1何志嵩,金杰,那彦群,郭应禄.α受体阻滞剂对良性前列腺增生患者症状的影响作用[J].中华泌尿外科杂志,2002,23(6):358-360. 被引量:19
  • 2Robertson C,Link CL,Onel E,et al. The impact of lower urinary tract symptoms and eomorbidities on quality of life:the BACH and UREPIK studies[J]. BJU Int, 2007,99 (2) : 347-354.
  • 3鲁欣,刘智勇,叶华茂,孙颖浩.盐酸坦索罗辛治疗伴有下尿路症状的BPH有效性和安全性研究[J].中华泌尿外科杂志,2010,31(9):624-628. 被引量:13
  • 4Rcade RO,Theret N ,Taieb C ,et al. Profile and anagement of patients treated for the first time for ower urinary tract symptoms/benign prostatic hyperplasia in four European countries[J]. BJU Int ,2008,101 (9) : 111- 118.
  • 5Ord APDW,Williams TJ,Blue DR,et al. a- drenoreceptor lassification: sharpening Occam's razor[J]. Trends Pharmacol Sci, 1994,15 (6):167- 171.
  • 6Hieble JP, Bylund DB, Clarke DE,et al. International union of pharmacology recommendation for nomenclature of arenoreceptor:consensus update[J]. Pharmacol Rev, 1995,47 (2) : 367-370.

二级参考文献19

  • 1沈文浩,熊恩庆,宋波.前列腺钬激光剜除术治疗良性前列腺增生近期疗效观察[J].中华泌尿外科杂志,2005,26(1):20-23. 被引量:24
  • 2虞巍,金杰.良性前列腺增生的联合药物治疗[J].中华泌尿外科杂志,2005,26(11):786-788. 被引量:19
  • 3王荫槐,刘任,杨罗艳.坦索罗辛对前列腺增生症患者性功能的影响[J].中国男科学杂志,2006,20(10):39-41. 被引量:7
  • 4De Mey C,Michel MC,McEwen J,et al.A double-blind comparison of terazosin and tamsulosin hydrochloride on there differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.Eur Urol,1998,33:481-488.
  • 5Buzelin JM,Fonteyne E,Kontturi M,et al.Comparison of tamsulosin hydrochloride with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction(symptomatic benign prostatic obstruction).Br J Urol,1997,80:597-605.
  • 6Lepor H.Phase Ⅲ multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia.Tamsulosin Investigator Group.Urology,1998,51:892-900.
  • 7Wilde MI,McTavish D.Tamsulosin hydrochloride.A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.Drugs,1996,52:883-898.
  • 8Schulman CC,Cortvriend J,Jonas U,et al.Tamsulosin hydrochloride.The first prostatic-selective α1 c-adrenoceptor antagonist:an interim analysis of a multinational,multicentre,open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH).Eur Urol,1996,29:145-154.
  • 9Lee M.Tamsulosin hydrochloride for the treatment of benign prostatic hypertrophy.Ann Pharmacother,2000,34:188-199.
  • 10Perinchery N.Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.J Urol,2003,170:498-502.

共引文献30

同被引文献66

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部